Patient Insights in the Pharmaceutical Industry

To continuously improve drug development, pharmaceutical companies assess if a medication is safe and increasingly ask if it actually works for those who will use it. Patients experience diseases differently from how they appear in clinical trial protocols or medical textbooks. Treatment burden, medication schedules, side effects, transportation, cost, caregiver responsibilities, and personal preferences can all influence whether a therapy succeeds in the real world. As a result, pharmaceutical companies increasingly incorporate patient insights throughout the drug development and commercialization process.

One way companies gather insights is by collaborating with patient advocacy groups. These organizations represent patients and caregivers affected by specific diseases and can provide perspectives that may not be captured through traditional clinical research. Pharmaceutical companies may engage with advocacy organizations to better understand unmet needs, challenges with diagnosis, treatment experiences, and priorities for future research. These relationships can be particularly important in rare diseases, where patient populations are small and individual experiences can provide valuable context.¹ Structured patient engagement can help researchers understand what matters most to the people ultimately affected by the disease.

Patient Journey Mapping

Another increasingly important tool is patient journey mapping. A patient journey describes the series of experiences a patient may encounter from the first appearance of symptoms through diagnosis, treatment, monitoring, and long-term disease management. For example, a patient with a chronic disease may experience months or years of symptoms before receiving an accurate diagnosis.² The patient might have multiple appointments, laboratory tests, medication changes, insurance hurdles, and treatment-related side effects. Mapping the journey allows pharmaceutical companies, healthcare professionals, and organizations to identify where patients experience the greatest challenges. These insights can influence clinical trial design, patient-support programs, educational materials, and the development of new therapies.

Patient insights can also influence clinical trial design and recruitment. Recruiting enough participants is one of the major challenges in clinical research, especially for rare diseases requiring highly specific eligibility criteria. Patients may face barriers such as frequent study visits, transportation requirements, complex procedures, time away from work, or uncertainty about trial participation. Understanding these obstacles can help sponsors design studies that are more practical for participants. Decentralized clinical trial approaches, remote monitoring, home health services, and more flexible visit schedules are examples of strategies that can potentially improve burdens of clinical trial participation when scientifically appropriate.³

Patient-Reported Outcomes

The patient perspective is also increasingly captured through patient-reported outcomes (PROs). A PRO is information about a patient's health status reported directly by the patient rather than interpreted by a clinician or another observer.⁴PROs can assess symptoms, physical functioning, emotional well-being, treatment-related side effects, and quality of life. These measurements can provide information that traditional clinical endpoints may not fully capture. For example, two treatments might produce similar laboratory results while patients experience meaningful differences in fatigue, pain, mobility, or daily functioning. Understanding patient experiences can help researchers develop a more complete picture of a treatment's benefits and risks.

Patient insights can also influence how pharmaceutical companies think about medication adherence and persistence. A medication can demonstrate meaningful efficacy in a clinical trial but produce less benefit in routine practice if patients struggle to take it consistently. Understanding why patients discontinue therapy can reveal deeper insights. Side effects, complicated dosing schedules, cost, lack of perceived benefit, inconvenience, and treatment fatigue can affect persistence. As a result, patient feedback can inform considerations such as formulation, dosing strategies, patient education, and support services.

The patient voice is very important for pharmaceutical companies planning commercialization and R&D initiatives. Patient insights can inform educational resources, adherence programs, disease-state education, and affordability initiatives. Patient insights can also help pharmaceutical companies identify unmet needs that may influence future research and development. After a medicine reaches the market, patients may identify challenges that were not obvious during clinical development. These insights can inform lifecycle-management strategies and future research. Companies may investigate alternative formulations, different dosing schedules, combination therapies, new delivery technologies, or additional indications that address some of these challenges. 

Closing Thoughts

For students and professionals in healthcare, understanding patient insights provides an important lesson about the difference between treating a disease and treating a patient. An impactful medication demonstrates efficacy while also providing an acceptable treatment experience, remaining accessible to appropriate patients, and fitting into the realities of everyday life. Patient advocacy groups, journey mapping, patient-reported outcomes, clinical trial engagement, treatment-preference research, and patient-informed commercialization provide opportunities to better understand those realities. Utilizing the patient voice in everyday practice provides valuable insight into pharmaceutical development as well as how medications move from scientific discoveries into beneficial treatments. 

References:

1. Forsythe LP, Szydlowski V, Murad MH, et al. A systematic review of approaches for engaging patients for research on rare diseases. J Gen Intern Med. 2014;29(3):S788-S800.
2. Maas VK, Dibbets FH, Peters VJT, Meijboom BR, van Bijnen D. The never-ending patient journey of chronically ill patients: A qualitative case study on touchpoints in relation to patient-centered care. PLoS One. 2023;18(5):e0285872.
3. Daly B, Brawley OW, Gospodarowicz MK, et al. Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Netw Open. 2024;7(4):e246228.
4. Williams LA. It's not just a questionnaire: The ins and outs of using a patient-reported outcome measure. Asia Pac J Oncol Nurs. 2025;12:100757.

*Information presented on RxTeach does not represent the opinion of any specific company, organization, or team other than the authors themselves. No patient-provider relationship is created.